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Abstract
Introduction This phase III, double-blind, randomised, placebo-controlled trial (and extension phase) was designed to assess the
efficacy and safety of velmanase alfa (VA) in alpha-mannosidosis (AM) patients.
Methods Twenty-five patients were randomised to weekly 1 mg/kg VA or placebo for 52 weeks. At study conclusion, placebo
patients switched to VA; 23 patients continued receiving VA in compassionate-use/follow-on studies and were evaluated in the
extension phase [last observation (LO)]. Co-primary endpoints were changes in serum oligosaccharide (S-oligo) and in the 3-min
stair-climb test (3MSCT).
Results Mean relative change in S-oligo in the VA arm was −77.6% [95% confidence interval (CI) −81.6 to −72.8] at week 52
and −62.9% (95% CI −85.8 to −40.0) at LO; mean relative change in the placebo arm was −24.1% (95% CI −40.3 to −3.6) at
week 52 and −55.7% (95%CI −76.4 to −34.9) at LO after switch to active treatment. Mean relative change in 3MSCTat week 52
was −1.1% (95% CI −9.0 to 7.6) and −% (95% CI −13.4 to 6.5) for VA and placebo, respectively. At LO, the mean relative
change was 3.9% (95%CI −5.5 to 13.2) in the VA arm and 9.0% (95%CI −10.3 to 28.3) in placebo patients after switch to active
treatment. Similar improvement pattern was observed in secondary parameters. A post hoc analysis investigated whether some
factors at baseline could account for treatment outcome; none of those factors were predictive of the response to VA, besides age.
Conclusions These findings support the utility of VA for the treatment of AM, with more evident benefit over time and when
treatment is started in the paediatric age.
Introduction
Alpha-mannosidosis (AM) is a rare autosomal recessive lyso-
somal storage disorder with a prevalence estimated at 1–
2:1,000,000 live births (Meikle et al. 1999; Meikle et al.
2004). AM is characterised by a deficiency of the lysosomal
enzyme, alpha-mannosidase, caused by pathogenic sequence
variants in the MAN2B1 gene. This deficiency leads to accu-
mulation of mannose-rich oligosaccharides, causing impaired
cellular function and apoptosis, which conversely leads to
significant and diverse adverse clinical manifestations (Beck
et al. 2013; Borgwardt et al. 2015). Currently, the only treat-
ment option for AM is allogeneic haematopoietic stem cell
transplantation (HSCT). However, not all patients are eligible
for HSCT or can be matched with compatible donors; HSCT
results are variable, and treatment carries mortality risks
(Mynarek et al. 2012; Danielsen et al. 2013).
Velmanase alfa is a recombinant human alpha-mannosidase
in development for weekly intravenously administered (IV)
enzyme replacement therapy (ERT) for AM (Borgwardt et al.
Communicated by: Carla E. Hollak
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10545-018-0185-0) contains supplementary
material, which is available to authorized users.
* Line Borgwardt
Line.Gutte.Borgwardt@regionh.dk
Extended author information available on the last page of the article
Journal of Inherited Metabolic Disease (2018) 41:1215–1223
https://doi.org/10.1007/s10545-018-0185-0
2013). Evaluation of velmanase alfa (VA) in phases I
(rhLAMAN-02; NCT01268358) and II (rhLAMAN-03/
rhLAMAN-04; NCT01285700/ NCT01681940) clinical stud-
ies showed a significant reduction in serum oligosaccharides at
18months and significant improvements in key clinical param-
eters of the disease (Borgwardt et al. 2014).
This paper reports results of the phase III clinical trial
(rhLAMAN-05; NCT01681953) designed to evaluate the ef-
ficacy and safety of 1 mg/kg weekly IV VA treatment com-
pared with placebo at 52 weeks in patients with AM.
Treatment dose was previously selected on the basis of the
phase I/II dose of 25 U/kg (Borgwardt et al. 2014), which
corresponds to 0.8 mg/kg, rounded to 1 mg/kg for calculation
convenience. Additional data from an extension phase
assessing the long-term effects of VA and describing the ef-




This Phase III, international, multicentre, double-blind,
randomised, placebo-controlled, parallel-group trial was de-
signed to investigate the efficacy and safety of VA treatment
of patients with AM. Patients who received VA during were
able to continue receiving treatment in a compassionate-use
(CU) programme/fol low-on t r ia l [ rhLAMAN-07
(NCT01908712) or rhLAMAN-09 (NCT01908725)]; partici-
pation in the CU programme vs follow-on trials depended on
national regulations]. Patients who received placebo could
switch to active treatment in the CU programme/follow-on
studies. Long-term outcomes of VA treatment were assessed
in comprehensive evaluation visits [last observation (LO)] un-
dertaken per protocol for patients enrolled in rhLAMAN-07 or
rhLAMAN-09 or as part of rhLAMAN-10 (open to patients
receiving treatment within the CU programme) and were car-
ried out in the same single centre. Data collected are presented
here as an extension-phase analysis to the phase III trial.
Patients
Patients with AM were screened for inclusion at Copenhagen
University Hospital, Denmark, and enrolled in different
European centres. Patients aged 5–35 years, with a confirmed
diagnosis of AM as defined by alpha-mannosidase activity
<10% of normal activity in blood leukocytes, and the ability
to cooperate physically andmentally in trial assessments, were
eligible for inclusion. Key exclusion criteria are listed in the
“Supplementary” section.
Procedures/treatment
All patients were evaluated for eligibility at the screening visit
(Visit −1). Patients who provided informed consent completed
a week of baseline assessments (Visit 0). Randomisation was
stratified by age, and patients were allocated into blocks of
five before randomisation in a 3:2 ratio to receive VA or pla-
cebo. Patients received IV infusion of VA 1 mg/kg or placebo
as part of Visit 1 (first infusion) and once weekly thereafter
(every seventh day ±3 days) for 52 weeks ±3 weeks. All effi-
cacy endpoints were evaluated at Copenhagen University
Hospital at weeks 26 and 52, with end-of-study visit at week
56. After completion of the phase III trial, patients either con-
tinued receiving active treatment, or switched from placebo to
active treatment, as part of the CU programme/follow-on trials
and contributed to assessment of long-term outcomes during
follow-on trials or as part of rhLAMAN-10.
Endpoints
The co-primary endpoints were change from baseline to week
52 in serum oligosaccharides and the 3-min stair climb test
(3MSCT). The prioritised secondary endpoints were change
from baseline to week 52 in the 6-min walk test (6MWT) and
in forced vital capacity percentage (FVC %, measured by
spirometry) of predicted normal value. Other secondary end-
points are detailed in the “Supplementary” section.
Treatment-emergent adverse events (TEAEs) were assessed
throughout the study and coded according to the Medical
Dictionary for Regulatory Activities (MedDRA), version
16.0. Vital signs, physical examination results, clinical labo-
ratory parameters and the development of VA antibodies were
assessed throughout the study. Serum immunoglobulin G
(IgG) levels were measured as part of the safety assessment.
Endpoint hierarchy was maintained in the extension phase.
Statistical analysis
No formal estimation of sample size was performed. The en-
rolment of 25 patients was deemed a good compromise be-
tween the limited availability of patients and the minimal
amount of data required for assessment of efficacy and safety.
Efficacy was defined as a statistically significant reduction in
serum oligosaccharides (P < 0.025) and a trend for improve-
ment in the 3MSCTand one prioritised secondary endpoint at
the 52-week analysis. Early study completion was allowed at
week 26 as per criteria reported in the “Supplementary”
section.
Analysis of primary and prioritised secondary endpoints
was performed on the relative change from baseline to week
52 in the full-analysis population. Data were log-transformed
and submitted to an analysis of covariance (ANCOVA), with
treatment as a fixed factor and corresponding baseline values
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and age as continuous covariates. Adjusted means in each
treatment group, adjusted mean difference between VA and
placebo, their 95% confidence intervals (CIs) and associatedP
values were estimated using this model. Additional informa-
tion regarding statistical analysis and post hoc analyses are
discussed in the “Supplementary” section.
For the extension-phase analysis, efficacy endpoints (actual
values, absolute change and percentage change from baseline)
were summarised for patients who received active treatment
throughout the phase 3 study (VA arm) and placebo-group pa-
tients who switched to active treatment poststudy completion
(placebo–VA switch arm). All analyses were descriptive only.
Results
Patients
Twenty-five European patients were enrolled and randomised
to receive VA (n = 15) or placebo (n = 10). One additional
patient was screened but not enrolled due to high IgE levels
(Supplementary Fig. 1). Prespecified criteria for early discon-
tinuation due to demonstrated efficacy were not reached at
week 26. The study was continued as blinded up to the 52-
week evaluation. Patient baseline characteristics are presented
in Supplementary Table 1. All 25 patients completed the phase
III study period and received VA treatment after study com-
pletion. Long-term follow-up data were available for 23 pa-
tients (Supplementary Fig. 1). Extension-phase analysis in-
cluded outcomes after 12–18 months of treatment exposure
for placebo-group patients who switched to active treatment,
and 24–36 months for patients who received active treatment
from the beginning of phase III. Compliance in the 12-month
phase III trial was >90% for all 25 patients.
Co-primary endpoints
Descriptive analyses of changes in serum oligosaccharide
levels by overall population and age subgroups from baseline
to LO are shown in Fig. 1a and Supplementary Fig. 2a. Mean
relative change in serum oligosaccharide concentration from
baseline to week 52 was greater in patients receiving VA (n =
15; −77.6%; 95% CI:–81.6 to −72.8) vs placebo (n = 10;
−24.1%; 95% CI:–40.3 to −3.6). The adjusted mean differ-
ence for VA vs placebo was −70.5% (95% CI –78.4 to
−59.7; P < 0.001). At LO, the mean relative change from
baseline was −62.9% (n = 13; 95% CI:–85.8 to −40.0) in the
VA arm and − 55.7% (n = 9; 95% CI:–76.4 to –34.9) in the
placebo–VA switch arm.
Descriptive analyses of absolute and relative changes in
3MSCT for the overall population and by age group from
baseline to LO visit are shown in Fig. 1b and Supplementary
Fig. 2b. Mean relative change in 3MSCT from baseline to
week 52 was −1.1% (95% CI –9.0 to 7.6) with VA and
− .0% (95% CI –13.4 to 6.5) with placebo [adjusted mean
difference for VA vs placebo: +3.0% (95% CI –9.86 to 17.7;
P = 0.648]]. At LO, mean relative change from baseline was
+3.9% (n = 13; 95%CI –5.5 to 13.2) in theVA arm and + 9.0%
(n = 9; 95% CI:–10.3 to 28.3) in the placebo–VA switch arm.
Prioritised secondary efficacy endpoints
Data for prioritised secondary endpoints by overall population
and age subgroups are shown in Table 1 and Supplementary
Fig. 3. A slight increase in the 6MWTat week 52 was seen in
the VA group compared with a slight decline in the placebo
group (not statistically significant). The adjusted mean differ-
ence in relative change for VAvs placebo was 1.9% (95%CI –
6.6 to 11.1; P = 0.66). At LO, the mean relative change was
0.7% (n = 13; 95% CI:–5.9 to 7.3) in the VA arm and 2.2%
(n = 9; 95% CI:–7.8 to 12.3) in the placebo–VA switch arm.
Change from baseline of FVC % resulted numerically in
favour (not statistically significant) of VA compared with pla-
cebo at week 52. The adjusted mean difference in relative
change for VA vs placebo was 8.4% (95% CI –6.1 to 25.1;
P = 0.27). At LO, mean relative change was 12.4% (n = 10;
95% CI 2.3 to 22.5) in the VA arm and 4.0 (n = 8; 95% CI:–
13.7 to 21.7) in the placebo–VA switch arm. The results of
additional secondary endpoints including audiometry, cere-
brospinal fluid biomarkers and use of help and aids are pre-
sented in Supplementary Tables 2–6.
Post hoc analysis of serum IgG showed a significant dif-
ference in mean absolute change from baseline to week 52
with VA treatment compared with placebo (Fig. 2) [be-
tween-group difference for VA vs placebo: 3.5 g/l (95% CI
2.1 to 4.8); P < 0.001]. At LO, mean relative change from
baseline in serum IgG was 47.2% (n = 14; 95% CI:30.2 to
64.3) in the VA arm and 37.3% (n = 9; 95% CI:24.9 to 49.7)
in the placebo–VA switch arm.
Safety
TEAEs are summarised in Table 2. Five serious TEAEs oc-
curred with VA treatment, of which four were considered as
unrelated to treatment. One case of moderate, acute renal fail-
ure considered possibly related to treatment occurred after
almost 12 months of treatment in a patient known to be re-
ceiving long-term concomitant ibuprofen. VAwas temporarily
suspended, and the patient recovered after 92 days. The pa-
tient restarted active treatment with no safety issues reported
and subsequently enrolled into the CU programme. No
TEAEs led to discontinuation from the study, and no deaths
were reported.
Eight patients (three in the VA group and five in the place-
bo arm) tested positive for anti-VA IgG antibodies (ADA+) on
at least one occasion before treatment (active or placebo); the
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three patients of the VA arm and two of the placebo switch
group had one positive results during on-treatment assess-
ments. All patients presented ADA levels around the set cutoff
level; just one patient receiving VA had ADA> 80 U/ml and
experienced infusion-related reactions (IRRs).
Discussion
In this phase III trial, VA was associated with a marked and
statistically significant clearance of serum oligosaccharides vs
placebo in patients with AM. This improvement in serum
oligosaccharide clearance continued into the extension phase.
Marginal clearance of oligosaccharides was also observed in
four patients of the placebo–VA switch arm, although this was
numerically smaller than in patients initially randomised to
active treatment; this is considered mainly due to spontaneous
fluctuations in oligosaccharide concentration at the 52-week
visit. Reducing the accumulation of mannosyl-rich oligosac-
charides in AM patients is assumed to target the root cause of
the systemic disease, since such accumulation is central to the
disease pathology and is considered related to cellular dys-
function (Malm et al. 2014). Due to the lack of power, no
statistically significant results were detected vs placebo in
a)
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Fig. 1 Mean absolute changes and mean relative changes in a serum oligosaccharides and b 3-min stair-climb test (3MSCT) from baseline to last
observation
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the motor and pulmonary function endpoints, but the changes
observed with VA treatment in the overall population resulted
consistently in the direction of a trend of improvement, espe-
cially in paediatric patients.
The combination of 3MSCT and 6MWT provides a robust
approach for evaluating the impact of ERT on patient endur-
ance. Stair climbing requires greater muscle strength and
range of joint motion than level walking and is therefore better
able to demonstrate functional difficulties (Nightingale et al.
2014). There was a marginal improvement in the 3MSCT for
VAvs placebo group. It should be noted that the placebo group
had better baseline functional status (40.0% patients accom-
plished ≥65 steps/min in the 3MSCT and ≥ 500 m in the
6MWT vs 13.3% in the VA group), suggesting that the pop-
ulation randomised to VA had greater motor limitation than
those in the placebo group.
Post hoc analysis revealed a better result (but not statis-
tically significant) of the 3MSCT in paediatric patients re-
ceiving VA compared with adults, suggesting that VA pro-
duces greater clinical benefits in motor function when ad-
ministered early in the disease course. Similar findings
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reported in other ERT studies (Muenzer 2014; Gabrielli
et al. 2010; Tylki-Szymanska et al. 2012; Tajima et al.
2013). In the extension phase, looking at patient-specific
results, greater improvements in 3MSCT can be observed
in patients in the placebo–VA switch arm compared with
patients initially randomised to the active treatment arm.
Two of the four adult patients who switched from placebo
to treatment showed an increase in 3MSCT at LO above
their initial baseline after declining during 12 months of
placebo treatment. One additional switch patient who im-
proved by 7.7 steps/min during the placebo phase further
improved by 15 steps/min in the first 12–18 months after
starting treatment. These patient-specific results are consis-
tent with a stabilisation (and in some cases improvement) of
motor endurance, even in adults.
At baseline, the paediatric subgroup reported values of
FVC compatible with a pulmonary restrictive syndrome
(Keddissi et al. 2013) but reverted to normal pulmonary func-
tion during the trial. These results suggest VA might prevent
worsening pulmonary function and may correct pulmonary
dysfunction in paediatric patients. The smaller improvements
observed in adults could be related to high baseline values
creating a ceiling effect or may indicate stabilisation in pul-
monary function decline.
Table 1 Summary of prioritised secondary endpoint results
Mean change from baseline to week 52* Mean change from baseline to last observationb
Velmanase alfa Placebo Velmanase alfa Placebo
6MWT
Overall population
Absolute change, mean (95% CI) n = 15
3.7 (−20.3 to 27.8)
n = 10
–3.6 (−33.1 to 25.9)
n = 13
2.8 (−28.3 to 34.0)
n = 9
3.2 (−36.0 to 42.5)
Percentage relative change (95% CI) n = 15
0.6 (−4.74 to 6.32)
n = 10
–1.2 (−7.63 to 5.68)
n = 13
0.7 (−5.9 to 7.3)
n = 9
2.2 (−7.8 to 12.3)
Paediatric population




































of predicted (95% CI)
n = 15
8.2 (1.8 to 14.6)
n = 10
2.3 (−6.2 to 10.8)
n = 10
12.4 (2.3 to 22.5)
n = 8
4.0 (−13.7 to 21.7)
Percentage relative change (95% CI) n = 15
10.1 (1.32 to 19.7)
n = 10

























Percentage relative change (SD) 2.3 (7.5) −4.1 (18.7) – –
6MWT 6-min walking test, CI confidence interval, FVC forced vital capacity, SD standard deviation
a Data presented in overall population are adjusted mean changes (95%CI) derived from analysis of covariance analyses; data for the paediatric and adult
populations were post hoc analyses and are summarised as mean (SD)
b Baseline to last observation analyses are descriptive only
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It is speculated that high levels of circulating oligosaccha-
rides (in addition to intracellular accumulation) may contrib-
ute to the immunodeficiency seen in AM patients, since they
bind to interleukin-2 (IL-2) receptors, disturbing IL-2-
dependent responses (Zanetta et al. 1998). Post hoc analyses
revealed a significant increase in serum IgG levels with VAvs
placebo, and an increase in levels in the placebo–VA switch
arm during the extension phase, suggesting that serum IgG
levels could be a potential biomarker of positive treatment
activity and response. Immunodeficiency is a major cause of
recurrent infections in AM patients and can lead to early
death; therefore, increased IgG levels may be relevant in
AM and have a therapeutic benefit. A postmarketing registry
study will help in understanding whether increased IgG cor-
relates with reduction of infection rates.
VA 1 mg/kg administered once weekly was well tolerated.
ADAs were detected in a limited number of participants, sug-
gestive of a clear and reproducible pharmacological effect
with VA. Only one patient developed a manifestly positive
ADA level and experienced IRR. The patient received
premedication prior to subsequent infusions and continued
to benefit from treatment with regard to motor function, sug-
gesting that IRRsmay be amanageable aspect of treatment. At
LO, the serum oligosaccharides presented as high as at base-
line, with persistence of high ADA levels.
The significant clearance of serum oligosaccharides in
this study is consistent with the findings of the phase II
study (Borgwardt et al. 2013). However, 3MSCT results
did not reach the same level of clinical improvement ob-
served at phase II. This may be accounted for by differences
in the patient population between the two studies. The en-
tirely paediatric phase II study population performed better
at baseline in the 3MSCT and 6MWT compared with the
phase III population, suggesting that clinical severity was
worse in phase III patients. Post hoc analyses have investi-
gated different baseline characteristics, such as age, gender,
genotype, residual enzymatic activity and disease burden
Table 2 Summary of treatment-
emergent adverse events during
the 12-month phase III study
period
Velmanase alfa n = 15 Placebo n = 10
No. of patients (%) Events No. of patients (%) Events
Any TEAEs 15 (100) 157 9 (90.0) 113
Treatment-related TEAEsa 7 (46.7) 30 5 (50.0) 9
Serious TEAEsb 5 (33.3) 5 0 (0.0) 0
Serious treatment-related TEAEs 1 (6.7) 1 0 (0.0) 0
Severe TEAEs 1 (6.7) 1 0 (0.0) 0
TEAEs with a fatal outcome 0 (0.0) 0 0 (0.0) 0
TEAEs leading to discontinuation 0 (0.0) 0 0 (0.0) 0
TEAEs treatment-emergent adverse events
a Treatment-related TEAEs were defined as having occurred in a reasonable temporal sequence from the time of
study-drug administration, abated upon discontinuation of the study drug and reappeared when treatment with the
study drug was restarted
b Serious TEAEs were defined as resulting in one of the following: death, life-threatening experience, a require-
ment for/prolongation of hospitalisation, a persistent or significant disability/incapacity, a congenital anomaly/
birth defect or an important medical event that jeopardised the patient or subject and may require medical or
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Fig. 2 Serum immunoglobulin changes in the overall population as
measured by a mean absolute change and b mean relative change
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measured by Childhood Health Assessment Questionnaire
(CHAQ) Disability Index (DI). No baseline factor was
found to be predictive of VA treatment outcome besides
age (data on file). Future postmarketing data collection
might shed light on possible baseline characteristic that
might predict treatment outcome, but based on data current-
ly available and the published medical literature on the dis-
ease, no conclusive observations can be made.
The efficacy endpoints in this study were assessed by the
same personnel at one central site, thus increasing the reliabil-
ity of collected results. However, there are limitations of the
study design; notably, the study population was small, which
is inevitable given the rarity of the disease, and it was also
heterogeneous and stratified by age but not by baseline dis-
ability. This led to imbalanced baseline endurance ability al-
location, which was poorer in the VA arm. Moreover, primary
and key secondary endpoints are to some extent dependent on
patient collaboration and understanding, enhancing the vari-
ability of results.
This study demonstrates the significant biological activity of
VA in reducing serum oligosaccharide levels and increasing se-
rum IgG across all ages. Positive changes in endurance and pul-
monary function with VA, particularly in paediatric patients with
subnormal respiratory function, suggests that greater clinical ben-
efits could be obtained if patients are diagnosed and begin treat-
ment early in the disease course (< 18 years). VAwas well toler-
ated, with no significant safety or immunogenicity concerns
raised. Comprehensive long-term data of the full clinical study
programme have been evaluated in the rhLAMAN-10 study and
integrated analysis (Lund et al. 2018; NCT02478840).
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